Sitimagene ceradenovec, a gene therapeutic for the treatment of glioma

Current Opinion in Molecular Therapeutics

Volumn 10, Issue 2, 2008, Pages 187-195

  Duzgunes N ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GANCICLOVIR; GENE THERAPY AGENT; SITIMAGENE CERADENOVEC; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRAIN EDEMA; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SYNTHESIS; FEVER; GENE THERAPY; GLIOMA; HEMIPARESIS; HERPES SIMPLEX VIRUS; HUMAN; INFLAMMATION; LOW DRUG DOSE; NONHUMAN; PATENT; REVIEW; SEIZURE; SIDE EFFECT;

ANIMALS; BRAIN NEOPLASMS; DRUG EVALUATION, PRECLINICAL; GENE THERAPY; GLIOMA; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDINE KINASE;

SIMPLEXVIRUS;

EID: 41849141976     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. 280191 Drug development pipeline: Suicide gene therapy (cancer), NIH. National Institutes of Health Company Communication 1998 March 05
2. 300593 Intracerebral injection of adenovirus harboring the HSVtk gene combined with ganciclovir administration: Toxicity study in nonhuman primates. Driesse MJ, Vincent AJPE, Sillevis Smitt PAE, Kros JM, Hoogerbrugge PM, Avezaat CJJ, Valerio D, Bout A Gene Ther 1998 5 8 1122-1129
3. 338497 Monitoring thymidine kinase and ganciclovir-induced changes in rat malignant glioma in vivo by nuclear magnetic resonance imaging. Poptani H, Puumalainen A-M, Grohn OH, Loimas S, Kainulainen R, Yla-Herttuala S, Kauppinen RA Cancer Gene Ther 1998 5 2 101-109
4. 338498 Quantitative 1H nuclear magnetic resonance diffusion spectroscopy of BT4C rat glioma during thymidine kinase-mediated gene therapy in vivo: Identification of apoptotic response. Hakumaki JM, Poptani H, Puumalainen A-M, Loimas S, Paljarvi LA, Yla-Herttuala S, Kauppinen RA CANCER RES 1998 58 17 3791-3799
5. 397954 AVAX and French army battle against GvHD. AVAX Technologies Inc Pres Release 2001 February 06
6. 404211 Ark's EG-009 gene therapy is very encouraging in phase I/IIa study. Ark Therapeutics Inc Pres Release 2001 April 05
7. 405101 Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Sandmair A-M, Loimas S, Puranen P, Immonen A, Kossila M, Puranen M, Hurskainen H, Tynnelä K, Turunen M, Vanninan R, Lehtolainen P et al Hum Gene Ther 2000 11 2197-2205
8. 405103 Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: Effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions. Sandmair A-M, Turunen M, Tynnelä K, Loimas S, Vainio P, Vanninan R, Vapalahti M, Bjerkvig R, Jänne J, Ylä-Herttuala S Cancer Gene Ther 2000 7 3 413-421
9. 405105 Low efficacy of gene therapy for rat BT4C malignant glioma using intra-tumoural transduction with thymidine kinase retrovirus packaging cell injections and ganciclovir treatment. Sandmair AM, Loimas S, Poptani H, Vainio P, Vanninen R, Turunen M, Tyynela K, Vapalahti M, Yla Herttuala S ACTA NEUROCHIR 1999 141 8 867-873
10. 443101 Gene Therapy - SMi Conference, London, UK. Ognjenovic M IDDB MEETING REPORT 2002 February 27-28
11. 542887 Ark's Cerepro increases survival in malignant glioma patients. Ark Therapeutics Ltd Pres release 2004 June 08
12. 555359 Acyclic/carbocyclic guanosine analogues as anti-herpesvirus agents. De Clercq E, Andrei G, Snoeck R, De Bolle L, Naesens L, Degrève B, Balzarini J, Zhang Y, Schols D, Leyssen P, Ying C et al NUCLEOSIDES NUCLEOTIDES NUCLEIC ACIDS 2001 20 4-7 271-285
13. 605912 Health departments of the United Kingdom: Gene Therapy Advisory Committee, 11th annual report. Internet site 2005 February 28
14. 631208 Cerepro marketing authorisation application review commences in Europe. Ark Therapeutics Ltd Pres release 2005 October 28
15. 631209 Ark commences Cerepro corroborative study. Ark Therapeutics Ltd Pres Release 2005 October 28
16. 686757 Ark Therapeutics Group plc interim results for the first half of 2006 - Progress continues in busy first half. Ark Therapeutics Group plc PRESS RELEASE 2006 August 30
17. 755657 Cerepro™ phase III trial progress update. Ark Therapeutics Group plc Pres release 2007 January 05
18. 772819 Products: Cerepro. Ark Therapeutics Group plc COMPANY WORLD WIDE WEB SITE 2007 March 09
19. 783691 AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomised, controlled study. Immonen A, Vapalahti M, Tynnelä K, Hurskainen H, Sandmair A, Vanninan R, Langford G, Murray N, Ylä-Herttuala S Mol Ther 2004 10 5 967-972
20. 783693 Assignment of 1H nuclear magnetic resonance visible polyunsaturated fatty acids in BT4C gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death. Griffin JL, Lehtimaki KK, Valonen PK, Grohn OHJ, Kettunen MI, Yla HS, Pitkanen A, Nicholson JK, Kauppinen RA Cancer Research 2003 63 12 3195-3201
21. 785162 Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with recurrent malignant brain tumors. Trask TW, Trask RP, Aguilar-Cordova E, Shine HD, Wyde PR, Goodman JC, Hamilton WJ, Rojas-Martinez A, Chen SH, Woo SLC, Grossman RG Mol Ther 2000 1 2 195-203
22. 785174 Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir: Pathologic, radiologic and molecular studies. Goodman JC, Trask TW, Chen SH, Woo SL, Grossman RG, Carey KD, Hubbard GB, Carrier DA, Rajagopalan S, Aguilar-Cordova E, Shine HD Hum Gene Ther 1996 7 10 1241-1250
23. 785183 Adenovirus-mediated gene therapy of experimental gliomas. Perez-Cruet MJ, Trask TW, Chen SH, Goodman JC, Grossman RG, Shine HD J Neurosci Res 1994 39 4 506-511
24. 791768 Committee for Medicinal Products for Human Use; April 2007 plenary meeting monthly report. European Agency for the Evaluation of Medicinal Products Pres release 2007 May 07
25. 812302 Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Moolten FL Cancer Res 1986 46 10 5276-5281
26. 812321 The HSV-tk/GCV gene therapy for brain tumors. Adachi N, Könü D, Frei K, Roth P, Yonekawa Y Gene Ther Mol Biol 1999 4 249-260
27. 812324 Gene therapy trials for the treatment of high-grade gliomas. Sonabend AM, Ulasov IV, Lesniak MS GEne Ther Mol Biol 2007 11 A 79-92
28. 812359 Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. Ohgaki H, Kleihues P J Neuropathol Exp Neurol 2006 64 6 479-489
29. 812361 Primary brain tumor incidence rates in four United States regions, 1985-1989: A pilot study. Davis FG, Malinski N, Haenszel W, Chang J, Flannery J, Gershman S, Dibble R, Bigner DD Neuroepidemiology 1996 15 2 103-112
30. 812364 Present and potential future issues in glioblastoma treatment. Lefranc F, Sadeghi N, Camby I, Metens T, Dewitte O, Kiss R Expert Rev Anticancer Ther 2006 6 5 719-732
31. 812365 Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy in BT4C glioma model. Tyynelä K, Sandmair A-M, Immonen A, Turunen M, Vanninan R, Vainio P, Kauppinen R, Johansson R, Vapalahti M, Ylä-Herttuala S Cancer Gene Ther 2002 9 11 917-924
32. 812370 Neurotoxicity of intracerebral injection of a replication-defective adenoviral vector in a semipermissive species (cotton rat). Shine HD, Wyde PR, Aguilar-Cordova E, Chen SH, Woo SLC, Grossman RG, Goodman JC Gene Ther 1997 4 4 275-279
33. 812373 β-Galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Puumalainen AM, Vapalahti M, Agrawal RS, Kossila M, Laukkanen J, Lehtolainen P, Viita H, Paljarvi L, Vanninen R, Yla-Herttuala S Hum Gene Ther 1998 9 12 1769-1774
34. 812380 Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: Preliminary results of a phase I trial in patients with recurrent malignant gliomas. Germano IM, Fable J, Gultekin SH, Silvers A J Neuro oncol 2003 65 3 279-289
35. 812528 Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex virus thymidine kinase gene followed by ganciclovir. Smitt PS, Driesse M, Wolbers J, Kros M, Avezaat C Mol Ther 2003 7 6 851-858
36. 812530 Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma. Zheng S, Ulasov IV, Han Y, Tyler MA, Zhu ZB, Lesniak MS J Gene Med 2007 9 3 151-160
37. 812637 Food and Drug Administration drug approval summary: Temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Cohen MH, Johnson JR, Pazdur R Clin Cancer Res 2005 11 19 Pt 1 6767-6771
38. 812639 Surgery, radiotherapy and temozolomide in treating highgrade gliomas. Parlato C, Barbarisi M, Moraci M, Moraci A Front Biosci 2006 11 1280-1283
39. 816538 DSMB recommends Ark's phase III Cerepro study for glioma continue. Ark Therapeutics Group plc PRESS RELEASE 2007 July 26
40. 867140 Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP CANCER 1993 71 8 2585-2597
41. 867142 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J et al N ENGL J MED 2005 352 10 987-996
42. 867350 Water diffusion in a rat glioma during ganciclovir-thymidine kinase gene therapy-induced programmed cell death in vivo: Correlation with cell density. Valonen PK, Lehtimäki KK, Väisänen TH, Kettunen MI, Gröhn OH, Ylä-Herttuala S, Kauppinen RA. J MAGN RESN IMAGING 2004 19 4 389-396
43. 868002 HSV-tk gene therapy for human renal cell carcinoma in nude mice. Pulkkanen KJ, Parkkinen JJ, Laukkanen JM, Kettunen MI, Tyynela K, Kauppinen RA, Ala-Opas MY, Yla-Herttuala S CANCER GENE THER 2001 8 7 529-536
44. 868239 The safety of adenoviral vectors containing the herpes simplex virus thymidine kinase gene. Langford G, Yla-Herttuala S, Boyd A ABSTRACTS WORLD FED NEURO-ONCOL MEETING 2005 Abs 395
45. 868241 Adenovirus-mediated herpes simplex thymidine kinase gene therapy for brain tumors. Sandmair AM, Vapalahti M, Ylä-Herttuala S ADV EXP MED BIOL 2000 465 163-170
46. 868410 Questions and answers on recommendations for the refusal of the marketing authorisation for Cerepro. European Agency for the Evaluation of Medicinal Products PRESS RELEASE 2007 April 26
47. 869123 Transduction efficiency of adenoviral vectors into human glioma cells increased by association with cationic liposomes. Ryuke Y, Mizuno M, Natsume A, Yoshida J NEUROL MED CHIR (TOKYO) 2000 40 5 256-260
48. 869126 RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-γ. Tjuvajev J, Gansbacher B, Desai R, Beattie B, Kaplitt M, Matei C, Koutcher J, Gilboa E, Blasberg R Cancer Res 1995 55 9 1902-1910
49. 878270 What is gene therapy? Drew J, Martin LA UNDERSTANDING GENE THER (ED: LEMOINE NR) Bios Scientific Publishers, Oxford, UK 1999 1-10
50. 881200 Transduction patterns and efficiencies in rabbit uterine tissues after intraluminal uterine adenovirus administration vary with the reproductive cycle. Laurema A, Lumme S, Heinonen SE, Heinonen S, Ylä-Herttuala S Acta Obstet Gynecol Scand 2007 86 9 1035-1040
51. 881207 Early gene therapy-induced apoptotic response in BT4C gliomas by magnetic resonance relaxation contrast T1 in the rotating frame. Hakumäki JM, Gröhn OH, Tyynelä K, Valonen P, Ylä-Herttuala S, Kauppinen RA Cancer Gene Ther 2002 9 4 338-345
52. 1H NMR spectroscopy in vivo, ex vivo, and in vitro. Lehtimäki KK, Valonen PK, Griffin JL, Väisänen TH, Gröhn OH, Kettunen MI, Vepsäläinen J, Ylä-Herttuala S, Nicholson J, Kauppinen RA J Biol Chem 2003 278 46 45915-45923
53. 881213 Novel magnetic resonance imaging contrasts for monitoring response to gene therapy in rat glioma. Gröhn OH, Valonen PK, Lehtimäki KK, Väisänen TH, Kettunen MI, Ylä-Herttuala S, Kauppinen RA, Garwood M Cancer Res 2003 63 22 7571-7574
54. 881682 Baculoviruses exhibit restricted cell type specificity in rat brain: A comparison of baculovirus- and adenovirus-mediated intracerebral gene transfer in vivo. Lehtolainen P, Tyynelä K, Kannasto J, Airenne KJ, Ylä-Herttuala S Gene Ther 2002 9 24 1693-1699
55. 882725 Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: Biological and clinical results. Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S, Berger MS, McDermott MW, Kunwar SM, Junck LR, Chandler W et al J CLIN ONCOL 2003 21 13 2508-2518
56. 882931 Ark Therapeutics - Company evolution. Ark Therapeutics Group plc COMPANY WORLD WIDE WEB SITE 2008 March 05
57. 882942 Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Moolten FL CANCER GENE THER 1994 1 4 279-287